Antibodies
25 September 2014
AbbVie’s HUMIRA® (adalimumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderately to Severely Active Crohn’s Disease25 September 2014
Novartis AIN457 (secukinumab) is the first ever IL-17A inhibitor to meet primary endpoint in two Phase III studies in psoriatic arthritis23 September 2014
Acceleron Provides Update on Externally Sponsored Clinical Trial of Dalantercept Monotherapy in Ovarian Cancer23 September 2014
Emergent BioSolutions Initiates Final Pivotal Study to Support Licensure of BioThrax at Large Scale23 September 2014
EPIRUS Announces Positive 58 Week Follow up Data for BOW015 for Treatment of Rheumatoid Arthritis22 September 2014
Amgen Submits Biologics License Application for Investigational BiTE® Immunotherapy Blinatumomab19 September 2014
FDA Approves Trulicity™ (dulaglutide), Lilly’s Once-Weekly Therapy for Adults with Type 2 Diabetes18 September 2014
CYRAMZA™ In Combination With Paclitaxel Significantly Improves Overall Survival In Second-Line Gastric Cancer Patients17 September 2014
Roche to present latest oncology advances during ESMO 2014 Congress17 September 2014
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer16 September 2014
EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema16 September 2014
Roche initiates phase III trials for lampalizumab, first potential treatment for geographic atrophy (GA)16 September 2014
EPIRUS’ Remicade® Biosimilar Receives Final Approvals in India16 September 2014
New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density15 September 2014
Kolltan Cancer Study Results for KTN3379, Targeting ErbB3, Support Evaluating Combinations with Targeted Therapies12 September 2014
Lilly Announces CYRAMZA™ Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival11 September 2014
At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received Genzyme’s Lemtrada in Pivotal Studies10 September 2014
Biotest completes recruitment in Phase IIb study (TREAT 2b) of Tregalizumab (BT-061) in patients with rheumatoid arthritis8 September 2014
Molecular Templates Announces FDA Approval of Investigational New Drug Application for CD20 Internalizing Immunotoxin MT-3724News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports